New drug dramatically improves survival in Hodgkin lymphoma patients

June 27, 2012

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

Loyola University Medical Center Scott E. Smith, MD, PhD presented survival data for the drug, brentuximab vedotin (Adcetris), at the 17th Congress of the European Association. Smith is director of Loyola's Hematological Malignancies Research Program.

The multi-center study included 102 Hodgkin who had relapsed after . Tumors disappeared in 32 percent of patients and shrank by at least half in 40 percent of patients. An additional 21 percent of patients experienced some . Only 6 percent of patients had no response to the drug.

Sixty five percent of patients were alive at 24 months, and in 25 percent of patients, the cancer had not progressed at all.

These are "encouraging results in patients with historically ," researchers said.

Loyola patient Michelle Salerno had failed two stem cell transplants -- one using her own cells and one using cells donated by her brother -- and multiple rounds of before going on brentuximab vedotin. After three or four infusions, she stopped suffering chills, sweats, high fevers and itchy pain from head to toe. And she experienced almost none of the side effects common to chemotherapy.

"I kept my hair, and never felt like vomiting," she said. "You get the drug, you go home, you feel good."

The standard regimen is a 30-minute infusion every three weeks. A patient typically receives 16 doses over 48 weeks.

Loyola has administered about 500 doses to 60 patients. "A lot of our patients are doing great on this regimen," Smith said.

Hodgkin is a cancer of the immune system. Most patients can be cured with chemotherapy or radiation, especially when the disease is diagnosed in early stages. However, if initial treatment fails, the patient may require an autologous stem cell transplant. This procedure uses the patient's own stem cells to replace immune system cells that are destroyed by high-dose chemotherapy or radiation.

About 50 percent of patients who undergo autologus stem cell transplants relapse. Among patients who relapse, only 10 percent survive.

The Food and Drug Administration last year approved brentuximab vedotin for patients who have either failed an autologous stem cell transplant, are ineligible for a stem cell transplant or have failed two multi-drug chemotherapy regimens.

Brentuximab vedotin is an antibody attached to a powerful chemotherapy drug. The antibody acts like a homing signal, bringing the chemo drug to lymphoma cells. "Brentuximab represents a very interesting new concept in the fight against cancer," said oncologist Tulio Rodriguez, MD, who treats Salerno and is medical director of Loyola's Bone Marrow Transplantation Program. "It delivers powerful chemotherapy right where it needs to be -- into the cancer cell."

Cancer patients frequently are debilitated not only by their cancer, but also by chemotherapy treatments. Targeted drugs such as brentuximab can spare patients from the harmful effects of traditional chemotherapy, Rodriguez said.

The study found that side effects from brentuximab were generally mild. Only 9 percent of patients suffered severe peripheral neuropathy, 2 percent had extreme fatigue and 1 percent had severe diarrhea.

Salerno said the only significant side effect she experienced was mild neuropathy, which went away when the dose was lowered.

Salerno, 43, has been battling for 10 years. Although she is not cured, she said, "I feel great and have a good quality of life."

Salerno, who lives in Lombard, said her treatments inspired her to start a business. She markets the Joey Pouch™ -- a small, soft pouch designed to comfortably hold the lumens of a central venous catheter so a patient can be more comfortable in daily activities or while sleeping. It is worn around the neck, next to the chest. The Joey Pouch is named after Salerno's brother, Joey, who donated stem cells used in one of her transplants.

Rodriguez said he feels immense satisfaction when he goes over CT scans with Salerno to show her how her disease is heading back into remission. But he cautioned that brentuximab, like all drugs, has potential toxicities. " should talk with their doctors about the pros and cons of taking this drug and discuss whether it is best for them," Rodriguez said.

Explore further: Brentuximab vedotin effective in large-cell lymphoma

Related Stories

Brentuximab vedotin effective in large-cell lymphoma

May 24, 2012
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, ...

Early transplants are no better than chemotherapy followed by transplant for NHL patients

June 6, 2011
Patients with a very aggressive form of non-Hodgkin lymphoma who receive a stem cell transplant after standard chemotherapy during their first remission have comparable survival rates to those who receive the same standard ...

Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

May 9, 2012
For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.